Bayer moves to block BDR's generic Nexavar in India
This article was originally published in Scrip
Executive Summary
German multinational Bayer has initiated legal action against BDR Life Sciences to block the latter's plans to introduce a generic version of the anticancer Nexavar (sorafenib tosylate) in India.